Dasatinib‐therapy induced sustained remission in a child with refractory TCF7 ‐ SPI1 T‐cell acute lymphoblastic leukemia
In: Pediatric Blood & Cancer, Jg. 69 (2022-04-20)
Online
unknown
Zugriff:
The prognosis of patients with T-cell acute lymphoblastic leukemia (T-ALL) has been largely lacked behind than that of patients with B-cell ALL, especially in refractory or relapsed cases. Here, we describe a 4.7-year-old male child with TCF-SPI1-postitve T-ALL who developed refractoriness disease after a seven drugs-conventional therapy. Several studies have suggested the therapeutic potential of dasatinib in refractory T-ALL. Actually, dasatinib-included therapy dramatically reduces the leukemic burden and re-induces this patient into complete remission without systemic adverse events. Although this is a single exceptional case, the translational potential evidence of dasatinib in specific T-ALL subtype should not be under-estimated.
Titel: |
Dasatinib‐therapy induced sustained remission in a child with refractory TCF7 ‐ SPI1 T‐cell acute lymphoblastic leukemia
|
---|---|
Autor/in / Beteiligte Person: | He, Yingyi ; Zhang, Jingliao ; Zhang, Yingchi ; Hu, Zhengbin ; Wang, Pengfei ; Gan, Wenting ; Xie, Shao ; Qian, Maoxiang ; Pui, Ching‐Hon ; Jiang, Hua ; Zhu, Xiaofan ; Zhang, Hui ; Zhang, Weina |
Link: | |
Zeitschrift: | Pediatric Blood & Cancer, Jg. 69 (2022-04-20) |
Veröffentlichung: | Wiley, 2022 |
Medientyp: | unknown |
ISSN: | 1545-5017 (print) ; 1545-5009 (print) |
DOI: | 10.1002/pbc.29724 |
Schlagwort: |
|
Sonstiges: |
|